Lung Cancer Dispatch
Follow
Find tag "dacomitinib"
4.3K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Pfizer Cancer Drug Fails in Two Late Stage Studies

In a recent phase III clinical trial, the cancer drug dacomitinib was no more effective than a placebo at prolonging survival for patients with advanced non-small cell lung cancer (NSCLC) for whom standard therapy had failed. Like the targeted drugs erlotinib (Tarceva) and gefitinib (Iressa), dacomitinib blocks the protein EGFR, but it also inhibits a number of similar, related proteins. Another trial compared dacomitinib to Tarceva in NSCLC patients who had previously received at least one EGFR inhibitor. Dacomitinib did not increase time without cancer worsening compared to Tarceva. Results from a third phase III trial, which compares dacomitinib to Iressa in NSCLC patients with EGFR mutations, are expected next year.

Cancer Commons's insight:

Bloomberg Businessweek  |  Jan 27, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Drug Outperforms Erlotinib in NSCLC Trial

New Drug Outperforms Erlotinib in NSCLC Trial | Lung Cancer Dispatch | Scoop.it

A new drug called dacomitinib proved more effective than erlotinib (Tarceva) in a recent clinical trial investigating non-small cell lung cancer (NSCLC) treatment. The results may be due to dacomitinib’s greater versatility—erlotinib targets only EGFR, while dacomitinib targets a whole family of proteins, including EGFR, that could contribute to tumor growth. Pfizer and SFJ Pharmaceuticals Group have announced plans to conduct a larger, multi-national clinical trial for dacomitinib.

Cancer Commons's insight:

HemOnc Today | Oct 25, 2012

more...
No comment yet.